in the N-AVD group had progression-free survival compared with 86% in the BV-AVD arm. N-AVD was also well-tolerated as there were few serious immune-related side effects in the S1826 trial. The median follow-up was 12.1 months.
"The results are remarkable. The combination of nivolumab and chemotherapy is potent and safe in patients with Stage 3 or 4 classic Hodgkin lymphoma as an," said Herrera,"The therapy is poised to be a standard for treatment of advanced Hodgkin lymphoma. This is indeed great news for patients with this cancer as there is another effective and safe treatment option for them."
Garabet met Herrera and instantly felt he was in good hands."He explained everything so well," he added. Garabet enrolled in the trial. After his first infusion, he felt exhausted but that was the worst he felt during treatment. After only four infusions, he was in remission. He was advised to continue the treatment in case any cancer lingered, and he did."Now when people tell me they have cancer, I tell them not to panic. There are a lot of cures now," he added.
"Hodgkin lymphoma is not a common disease and the NCTN enabled a large network of more than 200 pediatric and adult community providers and academic medical centers to work together. Because of that, we were able to get data very quickly and directly impact patient care. This was a critical investment in cancer research and treatment."
"The ability to maintain high rates of relapse-free survival with minimal use of radiation therapy in children with newly diagnosedHodgkin lymphoma will be a paradigm shift," said Sharon Castellino, M.D., M.Sc., chair of the COG Hodgkin lymphoma committee and director of the Leukemia and Lymphoma Program at the Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Winship Cancer Institute at Emory University.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Law Law Latest News, Law Law Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
For advanced, HER2-amplified bile duct cancers, antibody treatment trial shows promising resultsBile duct cancers are uncommon and aggressive types of gastrointestinal cancer. They include cholangiocarcinomas, which can form inside or outside of the liver, as well as cancers of the gallbladder, and are highly likely to cause serious disease or prove fatal.
Source: medical_xpress - 🏆 101. / 51 Read more »
Immunotherapy for brain cancer metastases shows clinical benefitIn a phase 2 clinical trial of the immune checkpoint inhibitor pembrolizumab, investigators found that 42 percent of patients with metastatic brain cancer benefited from the therapy, with seven patients in the trial surviving longer than two years.
Source: medical_xpress - 🏆 101. / 51 Read more »
Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a Phase I/II randomised double-blind placebo-controlled trial - DiabetologiaAim/hypothesis This study aimed to investigate the safety and efficacy of treatment with allogeneic Wharton’s jelly-derived mesenchymal stromal cells (MSCs) in recent-onset type 1 diabetes. Methods A combined Phase I/II trial, composed of a dose escalation followed by a randomised double-blind placebo-controlled study in parallel design, was performed in which treatment with allogeneic MSCs produced as an advanced therapy medicinal product (ProTrans) was compared with placebo in adults with newly diagnosed type 1 diabetes. Inclusion criteria were a diagnosis of type 1 diabetes 0.12 nmol/l. Randomisation was performed with a web-based randomisation system, with a randomisation code created prior to the start of the study. The randomisation was made in blocks, with participants randomised to ProTrans or placebo treatment. Randomisation envelopes were kept at the clinic in a locked room, with study staff opening the envelopes at the baseline visits. All participants and study personnel were blinded to group assignment. The study was conducted at Karolinska University Hospital, Stockholm, Sweden. Results Three participants were included in each dose cohort during the first part of the study. Fifteen participants were randomised in the second part of the study, with ten participants assigned to ProTrans treatment and five to placebo. All participants were analysed for the primary and secondary outcomes. No serious adverse events related to treatment were observed and, overall, few adverse events (mainly mild upper respiratory tract infections) were reported in the active treatment and placebo arms. The primary efficacy endpoint was defined as Δ-change in C-peptide AUC for a mixed meal tolerance test at 1 year following ProTrans/placebo infusion compared with baseline performance prior to treatment. C-peptide levels in placebo-treated individuals declined by 47%, whereas those in ProTrans-treated individuals declined by only 10% (p|0.05). Similarly, insulin requirements i
Source: medical_xpress - 🏆 101. / 51 Read more »
2023 Scott Plasma RC TT is The Fastest Bike Scott Have Ever MadeAll-new Scott Plasma RC TT time trial bike is the fastest thing on two wheels the Swiss bike maker has ever created, plus it’s super flexible…
Source: bikerumor - 🏆 65. / 61 Read more »
Sensory Adaptations to Reduce Distress During Dental Visits in Autistic ChildrenThis randomized crossover trial assesses physiological and behavioral distress in autistic children undergoing dental cleanings in a sensory-adapted dental environment compared with a regular dental environment.
Source: medical_xpress - 🏆 101. / 51 Read more »